This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
by Zacks Equity Research
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
INSMNegative Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechs earnings medical
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
by Zacks Equity Research
Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
XENENegative Net Change NBIXPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechs
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
by Zacks Equity Research
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
GILDPositive Net Change
biotechnology biotechs earnings pharmaceuticals
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
by Zacks Equity Research
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
IOVAPositive Net Change MRKPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechs earnings medical
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
by Zacks Equity Research
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
KYMRPositive Net Change SNYPositive Net Change GILDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.
PRGOPositive Net Change ALTPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechs
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
by Zacks Equity Research
SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
SRPTNo Net Change RHHBYPositive Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
by Zacks Equity Research
Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.
RVMDPositive Net Change BMYPositive Net Change MRKPositive Net Change SMMTPositive Net Change
biotechs earnings medical pharmaceuticals
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
by Zacks Equity Research
Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.
VTRSPositive Net Change RGENPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
by Zacks Equity Research
Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.
EXELPositive Net Change RHHBYPositive Net Change MRKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals